2018
CO-MORBIDITIES AND ETHNICITY/RACE PREDICT MORBIDITY AND MORTALITY IN HIGH RISK HEART FAILURE PATIENTS WITH SYSTOLIC DYSFUNCTION: THE GUIDE-IT PREDICTIVE RISK MODEL
O’Connor C, Fiuzat M, Coles A, Mulder H, Anstrom K, Ahmad T, Adams K, Pina I, Cooper L, Nickens P, Mark D, Ezekowitz J, Januzzi J, Leifer E, Felker G. CO-MORBIDITIES AND ETHNICITY/RACE PREDICT MORBIDITY AND MORTALITY IN HIGH RISK HEART FAILURE PATIENTS WITH SYSTOLIC DYSFUNCTION: THE GUIDE-IT PREDICTIVE RISK MODEL. Journal Of The American College Of Cardiology 2018, 71: a840. DOI: 10.1016/s0735-1097(18)31381-0.Peer-Reviewed Original Research
2013
Therapeutic Implications of Biomarkers in Chronic Heart Failure
Ahmad T, O'Connor C. Therapeutic Implications of Biomarkers in Chronic Heart Failure. Clinical Pharmacology & Therapeutics 2013, 94: 468-479. PMID: 23856627, DOI: 10.1038/clpt.2013.139.Peer-Reviewed Original ResearchConceptsChronic heart failureHeart failureTherapeutic implicationsBiomarker-guided clinical trialsTreatment of HFPotential therapeutic implicationsClinical trial designImportant therapeutic implicationsUse of biomarkersHemodynamic disordersClinical trialsClinical careTrial designTherapeutic potentialBiomarker studiesMolecular biomarkersBiomarkersMolecular dysfunctionMolecular pathwaysDysfunctionFailurePathophysiologySyndromeTrialsCare